Contemporary anticoagulant treatment strategies in patients with acute pulmonary embolism at different risk for death
CONCLUSIONS: Contemporary anticoagulation for acute PE includes parenteral agents in over 90% of patients; DOACs are used in the large majority of PE patients at discharge and their early use seems effective and safe also in selected intermediate-risk patients.TRIAL REGISTRATION NUMBER: NCT03631810.PMID:38013135 | DOI:10.1016/j.vph.2023.107245 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - November 28, 2023 Category: Drugs & Pharmacology Authors: Cecilia Becattini Giancarlo Agnelli Michele Diamanti Aldo P Maggioni Simone Vanni Francesco Dentali Iolanda Enea Paola Bortolotti Massimiliano De Vecchi Nicola Artusi Claudio Picariello Cinzia Nitti Donata Lucci Michele M Gulizia COPE Investigators Source Type: research
Contemporary anticoagulant treatment strategies in patients with acute pulmonary embolism at different risk for death
CONCLUSIONS: Contemporary anticoagulation for acute PE includes parenteral agents in over 90% of patients; DOACs are used in the large majority of PE patients at discharge and their early use seems effective and safe also in selected intermediate-risk patients.TRIAL REGISTRATION NUMBER: NCT03631810.PMID:38013135 | DOI:10.1016/j.vph.2023.107245 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - November 28, 2023 Category: Drugs & Pharmacology Authors: Cecilia Becattini Giancarlo Agnelli Michele Diamanti Aldo P Maggioni Simone Vanni Francesco Dentali Iolanda Enea Paola Bortolotti Massimiliano De Vecchi Nicola Artusi Claudio Picariello Cinzia Nitti Donata Lucci Michele M Gulizia COPE Investigators Source Type: research
Contemporary anticoagulant treatment strategies in patients with acute pulmonary embolism at different risk for death
CONCLUSIONS: Contemporary anticoagulation for acute PE includes parenteral agents in over 90% of patients; DOACs are used in the large majority of PE patients at discharge and their early use seems effective and safe also in selected intermediate-risk patients.TRIAL REGISTRATION NUMBER: NCT03631810.PMID:38013135 | DOI:10.1016/j.vph.2023.107245 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - November 28, 2023 Category: Drugs & Pharmacology Authors: Cecilia Becattini Giancarlo Agnelli Michele Diamanti Aldo P Maggioni Simone Vanni Francesco Dentali Iolanda Enea Paola Bortolotti Massimiliano De Vecchi Nicola Artusi Claudio Picariello Cinzia Nitti Donata Lucci Michele M Gulizia COPE Investigators Source Type: research
Efficacy and safety of tirofiban in patients with acute ischemic stroke treated with endovascular thrombectomy: A frequentist and Bayesian meta-analysis
CONCLUSION: For patients with AIS treated with EVT, tirofiban improved FFOs, decreased mortality, and did not increase SICH compared with controls; postbolus infusion for administering tirofiban was more favored than the bolus-only regimen.PMID:37992511 | DOI:10.1016/j.vph.2023.107244 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - November 22, 2023 Category: Drugs & Pharmacology Authors: Wei-Zhen Lu Hui-An Lin Sen-Kuang Hou Chyi-Huey Bai Sheng-Feng Lin Source Type: research
Efficacy and safety of tirofiban in patients with acute ischemic stroke treated with endovascular thrombectomy: A frequentist and Bayesian meta-analysis
CONCLUSION: For patients with AIS treated with EVT, tirofiban improved FFOs, decreased mortality, and did not increase SICH compared with controls; postbolus infusion for administering tirofiban was more favored than the bolus-only regimen.PMID:37992511 | DOI:10.1016/j.vph.2023.107244 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - November 22, 2023 Category: Drugs & Pharmacology Authors: Wei-Zhen Lu Hui-An Lin Sen-Kuang Hou Chyi-Huey Bai Sheng-Feng Lin Source Type: research
Efficacy and safety of tirofiban in patients with acute ischemic stroke treated with endovascular thrombectomy: A frequentist and Bayesian meta-analysis
CONCLUSION: For patients with AIS treated with EVT, tirofiban improved FFOs, decreased mortality, and did not increase SICH compared with controls; postbolus infusion for administering tirofiban was more favored than the bolus-only regimen.PMID:37992511 | DOI:10.1016/j.vph.2023.107244 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - November 22, 2023 Category: Drugs & Pharmacology Authors: Wei-Zhen Lu Hui-An Lin Sen-Kuang Hou Chyi-Huey Bai Sheng-Feng Lin Source Type: research
Efficacy and safety of tirofiban in patients with acute ischemic stroke treated with endovascular thrombectomy: A frequentist and Bayesian meta-analysis
CONCLUSION: For patients with AIS treated with EVT, tirofiban improved FFOs, decreased mortality, and did not increase SICH compared with controls; postbolus infusion for administering tirofiban was more favored than the bolus-only regimen.PMID:37992511 | DOI:10.1016/j.vph.2023.107244 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - November 22, 2023 Category: Drugs & Pharmacology Authors: Wei-Zhen Lu Hui-An Lin Sen-Kuang Hou Chyi-Huey Bai Sheng-Feng Lin Source Type: research
MINOCA: Diagnostic work-up, risk stratification and tailored therapies
Vascul Pharmacol. 2023 Nov 14:107243. doi: 10.1016/j.vph.2023.107243. Online ahead of print.ABSTRACTMyocardial infarction with no obstructive coronary artery disease (MINOCA) diagnostic work-up, risk stratification and tailored therapies are emerging as the recognition of this type of MI is increasingly recognized. Diagnostic workup using advanced imaging can include coronary angiography/intravascular ultrasound (IVUS)/optical coherent tomography (OCT), echo and cardiac magnetic resonance imaging (MRI). Risk stratification portends an intermediate risk compared to multivessel obstructive coronary artery disease (CAD). Whil...
Source: Vascular Pharmacology - November 16, 2023 Category: Drugs & Pharmacology Authors: C Noel Bairey Merz Martha Gulati Janet Wei Source Type: research
MINOCA: Diagnostic work-up, risk stratification and tailored therapies
Vascul Pharmacol. 2023 Nov 14:107243. doi: 10.1016/j.vph.2023.107243. Online ahead of print.ABSTRACTMyocardial infarction with no obstructive coronary artery disease (MINOCA) diagnostic work-up, risk stratification and tailored therapies are emerging as the recognition of this type of MI is increasingly recognized. Diagnostic workup using advanced imaging can include coronary angiography/intravascular ultrasound (IVUS)/optical coherent tomography (OCT), echo and cardiac magnetic resonance imaging (MRI). Risk stratification portends an intermediate risk compared to multivessel obstructive coronary artery disease (CAD). Whil...
Source: Vascular Pharmacology - November 16, 2023 Category: Drugs & Pharmacology Authors: C Noel Bairey Merz Martha Gulati Janet Wei Source Type: research
MINOCA: Diagnostic work-up, risk stratification and tailored therapies
Vascul Pharmacol. 2023 Nov 14:107243. doi: 10.1016/j.vph.2023.107243. Online ahead of print.ABSTRACTMyocardial infarction with no obstructive coronary artery disease (MINOCA) diagnostic work-up, risk stratification and tailored therapies are emerging as the recognition of this type of MI is increasingly recognized. Diagnostic workup using advanced imaging can include coronary angiography/intravascular ultrasound (IVUS)/optical coherent tomography (OCT), echo and cardiac magnetic resonance imaging (MRI). Risk stratification portends an intermediate risk compared to multivessel obstructive coronary artery disease (CAD). Whil...
Source: Vascular Pharmacology - November 16, 2023 Category: Drugs & Pharmacology Authors: C Noel Bairey Merz Martha Gulati Janet Wei Source Type: research
MINOCA: Diagnostic work-up, risk stratification and tailored therapies
Vascul Pharmacol. 2023 Nov 14:107243. doi: 10.1016/j.vph.2023.107243. Online ahead of print.ABSTRACTMyocardial infarction with no obstructive coronary artery disease (MINOCA) diagnostic work-up, risk stratification and tailored therapies are emerging as the recognition of this type of MI is increasingly recognized. Diagnostic workup using advanced imaging can include coronary angiography/intravascular ultrasound (IVUS)/optical coherent tomography (OCT), echo and cardiac magnetic resonance imaging (MRI). Risk stratification portends an intermediate risk compared to multivessel obstructive coronary artery disease (CAD). Whil...
Source: Vascular Pharmacology - November 16, 2023 Category: Drugs & Pharmacology Authors: C Noel Bairey Merz Martha Gulati Janet Wei Source Type: research
Endothelial heterogeneity and their relevance in cardiac development and coronary artery disease
Vascul Pharmacol. 2023 Nov 6:107242. doi: 10.1016/j.vph.2023.107242. Online ahead of print.ABSTRACTMicro- and macrovascular endothelial cells (ECs) are characterized by structural and functional heterogeneity, which is also reflected in their secretory activity. The root of this heterogeneity and related regulatory mechanisms are still poorly understood. During embryogenesis, microvascular ECs participate in organogenesis prior to the development of the fetal circulation, suggesting that ECs are capable of releasing paracrine trophogens, termed angiocrine factors (AFs). These are angiocrine growth factors, adhesion molecul...
Source: Vascular Pharmacology - November 8, 2023 Category: Drugs & Pharmacology Authors: Rosalinda Madonna Source Type: research
Endothelial heterogeneity and their relevance in cardiac development and coronary artery disease
Vascul Pharmacol. 2023 Nov 6:107242. doi: 10.1016/j.vph.2023.107242. Online ahead of print.ABSTRACTMicro- and macrovascular endothelial cells (ECs) are characterized by structural and functional heterogeneity, which is also reflected in their secretory activity. The root of this heterogeneity and related regulatory mechanisms are still poorly understood. During embryogenesis, microvascular ECs participate in organogenesis prior to the development of the fetal circulation, suggesting that ECs are capable of releasing paracrine trophogens, termed angiocrine factors (AFs). These are angiocrine growth factors, adhesion molecul...
Source: Vascular Pharmacology - November 8, 2023 Category: Drugs & Pharmacology Authors: Rosalinda Madonna Source Type: research
Endothelial heterogeneity and their relevance in cardiac development and coronary artery disease
Vascul Pharmacol. 2023 Nov 6:107242. doi: 10.1016/j.vph.2023.107242. Online ahead of print.ABSTRACTMicro- and macrovascular endothelial cells (ECs) are characterized by structural and functional heterogeneity, which is also reflected in their secretory activity. The root of this heterogeneity and related regulatory mechanisms are still poorly understood. During embryogenesis, microvascular ECs participate in organogenesis prior to the development of the fetal circulation, suggesting that ECs are capable of releasing paracrine trophogens, termed angiocrine factors (AFs). These are angiocrine growth factors, adhesion molecul...
Source: Vascular Pharmacology - November 8, 2023 Category: Drugs & Pharmacology Authors: Rosalinda Madonna Source Type: research
Endothelial heterogeneity and their relevance in cardiac development and coronary artery disease
Vascul Pharmacol. 2023 Nov 6:107242. doi: 10.1016/j.vph.2023.107242. Online ahead of print.ABSTRACTMicro- and macrovascular endothelial cells (ECs) are characterized by structural and functional heterogeneity, which is also reflected in their secretory activity. The root of this heterogeneity and related regulatory mechanisms are still poorly understood. During embryogenesis, microvascular ECs participate in organogenesis prior to the development of the fetal circulation, suggesting that ECs are capable of releasing paracrine trophogens, termed angiocrine factors (AFs). These are angiocrine growth factors, adhesion molecul...
Source: Vascular Pharmacology - November 8, 2023 Category: Drugs & Pharmacology Authors: Rosalinda Madonna Source Type: research
